# 2026-06379: Rocket Pharma Scores Fast-Track Voucher for Kids' Rare Disease Drug

2026-06379, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegragene autotemcel), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-02, effective 2026-03-26; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-06379
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-06379
- Title: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegragene autotemcel)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 16714
- Published: 2026-04-02
- Effective: 2026-03-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Rocket Pharma Scores Fast-Track Voucher for Kids' Rare Disease Drug

## Summary

The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that KRESLADI (marnetegragene autotemcel), approved March 26, 2026, manufactured by Rocket Pharmaceuticals, Inc., meets the criteria for a priority review voucher.

## Effects PRIA read

- Priority Review Voucher Awarded: benefit, medium. The FDA issued a priority review voucher to Rocket Pharmaceuticals for KRESLADI, with the drug approved on March 26, 2026. The voucher can be used to obtain a faster FDA review for a future drug application under the Rare Pediatric Disease Priority Review Voucher Program.
- New Pediatric Treatment Approval: benefit, medium. A new treatment, KRESLADI (marnetegragene autotemcel), was approved on March 26, 2026 for pediatric patients with severe leukocyte adhesion deficiency-I (LAD‑I) caused by biallelic ITGB2 variants when an HLA‑matched sibling donor for transplant is not available. If you have a child with this condit…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-06379 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/02/2026-06379/issuance-of-priority-review-voucher-rare-pediatric-disease-product-kresladi-marnetegragene)
- [2026-06379 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-02/pdf/2026-06379.pdf)

## Related
- [Previous: 2026-06378, Parts and Accessories Necessary for Safe Operation; Application for Exemption R…](https://policyrisk.com/federal-register/2026-06378)
- [Next: 2026-06380, Combined Notice of Filings #1](https://policyrisk.com/federal-register/2026-06380)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-06379 (as of 2026-06-08).
